RESUMEN
The first results of the study of high-energy electron neutrino (ν_{e}) and muon neutrino (ν_{µ}) charged-current interactions in the FASERν emulsion-tungsten detector of the FASER experiment at the LHC are presented. A 128.8 kg subset of the FASERν volume was analyzed after exposure to 9.5 fb^{-1} of sqrt[s]=13.6 TeV pp data. Four (eight) ν_{e} (ν_{µ}) interaction candidate events are observed with a statistical significance of 5.2σ (5.7σ). This is the first direct observation of ν_{e} interactions at a particle collider and includes the highest-energy ν_{e} and ν_{µ} ever detected from an artificial source. The interaction cross section per nucleon σ/E_{ν} is measured over an energy range of 560-1740 GeV (520-1760 GeV) for ν_{e} (ν_{µ}) to be (1.2_{-0.7}^{+0.8})×10^{-38} cm^{2} GeV^{-1} [(0.5±0.2)×10^{-38} cm^{2} GeV^{-1}], consistent with standard model predictions. These are the first measurements of neutrino interaction cross sections in those energy ranges.
RESUMEN
We report the first direct observation of neutrino interactions at a particle collider experiment. Neutrino candidate events are identified in a 13.6 TeV center-of-mass energy pp collision dataset of 35.4 fb^{-1} using the active electronic components of the FASER detector at the Large Hadron Collider. The candidates are required to have a track propagating through the entire length of the FASER detector and be consistent with a muon neutrino charged-current interaction. We infer 153_{-13}^{+12} neutrino interactions with a significance of 16 standard deviations above the background-only hypothesis. These events are consistent with the characteristics expected from neutrino interactions in terms of secondary particle production and spatial distribution, and they imply the observation of both neutrinos and anti-neutrinos with an incident neutrino energy of significantly above 200 GeV.
RESUMEN
KRAS mutation testing before anti-epidermal growth factor receptor therapy of metastatic colorectal cancer has become mandatory in Europe. However, considerable uncertainty exists as to which methods for detection can be applied in a reproducible and economically sound manner in the routine diagnostic setting. To answer this question, we examined 263 consecutive routine paraffin slide specimens. Genomic DNA was extracted from microdissected tumor tissue. The DNA was analyzed prospectively by Sanger sequencing and array analysis as well as retrospectively by melting curve analysis and pyrosequencing; the results were correlated to tissue characteristics. The methods were then compared regarding the reported results, costs, and working times. Approximately 40% of specimens contained KRAS mutations, and the different methods reported concordant results (kappa values >0.9). Specimens harboring fewer than 10% tumor cells showed lower mutation rates regardless of the method used, and histoanatomical variables had no influence on the frequency of the mutations. Costs per assay were higher for array analysis and melting curve analysis when compared with the direct sequencing methods. However, for sequencing methods equipment costs were much higher. In conclusion, Sanger sequencing, array analysis, melting curve analysis, and pyrosequencing were equally effective for routine diagnostic KRAS mutation analysis; however, interpretation of mutation results in conjunction with histomorphologic tissue review and on slide tumor tissue dissection is required for accurate diagnosis.